Fibrosis is the end-stage of chronic inflammatory diseases and tissue damage resulting from a dysregulated wound-healing response [1] . Most organs can develop scarring tissue in association with different pathological states including chronic inflammation, autoimmune disorders, graft rejection, malignant tumors or unknown factors [1] . Organ fibrosis is the cause of about 45% of the worldwide total death in developed countries [2] . The high frequency of co-morbidities, the increased mortality rate, the enigma surrounding the disease pathogenesis and the lack of effective therapeutic modalities have made organ fibrosis an area of great interest and consequently the focus of many investigations in recent years [3, 4] . This special issue, "Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges", depicts original findings on intracellular signaling pathways playing a role in fibrogenesis and carcinogenesis associated with chronic diseases and metabolic disorders, and includes reviews describing recent discoveries on potential pathogenic factors, pathophysiological insights, and novel treatment options.
etiology [14] . There are similarities between IPF and cancer in terms of clinical behavior and molecular pathways underlying the pathogenesis of the disease [13, 15, 16] . Both diseases are characterized by poor response to therapy, short life expectancy, and frequent exposure to harmful environmental factors (e.g., cigarette smoke) [16] . Indeed, the prognosis of idiopathic pulmonary fibrosis is poorer than most types of cancer except malignant tumors of the lung or pancreas [17] . As outlined in this special issue, idiopathic pulmonary fibrosis shares common features with cancer in terms of genetic and epigenetic changes, abnormalities in cell-to-cell communication, aberrant activation of intracellular signal pathways, deregulated expression of growth factors/proteolytic enzymes, uncontrolled cell apoptosis and activation of pro-fibrotic cells [13] . This concept of close-identity between aberrant tissue scarring and cancer is not restricted to the lungs. Although at variable levels, most organs with either fibrotic, benign or malignant disease show abnormal activation of similar signaling and mechanistic pathways [15, [18] [19] [20] . Fibroblast is one of these common components of cancer and fibrotic disease that plays detrimental roles by contributing to disease progression [6, [10] [11] [12] 21] . Cancer-and scarring tissue-associated fibroblasts may further differentiate to myofibroblasts by cytokines and growth factors such as transforming growth factorβ1 to expand the desmoplastic tissue in both pathologies and to promote cell invasiveness and resistance to therapy in malignant tumors [6, 10, 11] . Studies evaluating the phenotypic and behavioral alterations of cellular mediators, and biochemical and molecular abnormalities common to organ injury, fibrosis and malignant diseases may provide hints for the development of new diagnostic approaches and effective and less toxic therapeutic modalities for both diseased conditions [22] [23] [24] [25] [26] .
Recent discoveries in science and advances in technology have revolutionized the diagnostic procedures and therapeutic approaches of many diseases leading to a significant amelioration of quality-of-life and prognosis. However, the incidence and burden of organ fibrosis and cancer are still increasing worldwide [27] [28] [29] . Much work remains to be done to achieve more timely diagnosis and to improve the therapeutic management of fibrotic and malignant diseases. The recent insights into the pathogenesis of organ fibrogenesis and malignancy and the new potential therapeutic targets described in the present special issue may be useful for identifying new biological markers and for drug discovery.
